ABSTRACT
This case study describes severe iatrogenic botulism following treatment with a botulinum toxin injection at a private clinic abroad.
Subject(s)
Botulinum Toxins, Type A , Botulism , Clostridium botulinum , Humans , Botulism/diagnosis , Botulism/etiology , Botulism/therapy , Ambulatory Care Facilities , Iatrogenic DiseaseABSTRACT
BACKGROUND: COVID-19 pneumonia can result in severe hypoxaemic respiratory failure that requires intensive medical care. We wished to describe COVID-19 intensive care patients who were treated with and without invasive ventilatory support. MATERIAL AND METHOD: The material was retrieved from the local quality register and comprises data on patients with COVID-19 admitted to the intensive care department at Oslo University Hospital Ullevål from 5 March-28 May 2020. The patients were categorised in three groups on the basis of the treatment they received for respiratory failure (oxygen alone, supplemental non-invasive ventilation (NIV), and intubation/ventilator) and described using descriptive statistics. RESULTS: Of 165 hospitalised COVID-19 patients, a total of 26 (16 %) were treated in our intensive care department. Four of them had do-not-resuscitate-orders and were excluded. The 22 patients included in this study had an average age of 56 years (range 25 to 78 years); 17 (77 %) were men. Eleven patients received ventilator treatment, seven oxygen by mask, and four supplemental NIV. In the ventilator group, as of 28 May 2020 two had died, and the remainder had been discharged alive from the intensive care department, with one remaining hospitalised on a ward. All patients treated with oxygen and NIV were alive and had been discharged from hospital. INTERPRETATION: For many patients with COVID-19 respiratory failure and need for intensive care, increased oxygen and NIV are sufficient, but the need for intubation must be continuously assessed. More than 90 % of actively treated intensive care patients survived.
Subject(s)
Coronavirus Infections/therapy , Noninvasive Ventilation , Pneumonia, Viral/therapy , Respiration, Artificial , Respiratory Insufficiency/therapy , Adult , Aged , Betacoronavirus , COVID-19 , Critical Care , Female , Humans , Intensive Care Units , Male , Middle Aged , Norway , Oxygen/therapeutic use , Pandemics , Respiratory Insufficiency/virology , SARS-CoV-2ABSTRACT
OBJECTIVE: To evaluate anion and osmolal gaps as diagnostic tools in methanol poisoning. DESIGN AND SETTING: Clinical observational study. PATIENTS AND METHODS: In a recent methanol outbreak, the initial triage and treatment decisions in 28 patients were based mainly upon the values of the osmolal and anion gaps on admission. Methanol and formate levels were later compared to these gaps by linear regression analysis. RESULTS: The correlation between the osmolal gaps and serum methanol concentrations on admission was linear (y = 1.03x+12.71, R2 = 0.94). The anion gaps correlated well with the serum formate concentrations (y = 1.12x+13.82, R2 = 0.86). Both gaps were elevated in 24 of the 28 subjects upon admission. Three patients had an osmolal gap within the reference area (because of low serum methanol), but elevated anion gap because of formate accumulation. One patient with probable concomitant ethanol ingestion had a high osmolal gap and a normal anion gap. CONCLUSION: Osmolal and anion gaps are useful in the diagnosis and triage of methanol-exposed subjects. Confounders are low serum methanol and concomitant ethanol ingestion.
Subject(s)
Acid-Base Equilibrium , Methanol/poisoning , Poisoning/blood , Acidosis/diagnosis , Chromatography, Gas , Formates/blood , Humans , Linear Models , Methanol/blood , Observation , Poisoning/diagnosis , Solvents/analysis , Solvents/poisoningABSTRACT
BACKGROUND: Severe sepsis is a common cause of mortality in critically ill patients. Drotrecogin alfa (activated), synonymous with recombinant human activated protein C (rhAPC), is a new therapeutic tool with anticoagulant, anti-inflammatory and profibrinolytic properties with proven effect in reducing mortality in severe sepsis. MATERIAL AND METHODS: As part of a multi-centre study, the patients received an infusion of rhAPC, 24 microg/kg/h for 96 hours according to an open-labeled phase IIIb study protocol. RESULTS: Out of a total of 28 patients, 6 (21%) died before day 28. One of the deaths was classified as possibly related to rhAPC. In three patients rhAPC was transiently stopped because of surgery or postoperative bleeding. Use of the compound rarely interfered with commonly used diagnostic and therapeutic procedures. INTERPRETATION: Treatment with rhAPC is easily carried out in an intensive care unit. Patients with severe sepsis and two or more failing vital organs should be considered for treatment with rhAPC.
